Long-term survival benefits were seen in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) using the drug acoramidis (Attruby) in new data presented at the American College of Cardiology (ACC) 2026 meeting extending out to 54 months from the original FDA pivotal trial.
Cardiovascular Business spoke with the late-breaking presenter Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute, in the above video to get more details.